Dexcom’s G7 is in front of the FDA right now. There are some significant changes to the system, including what’s basically a snooze for essential alarms, including the urgent low. Dexcom’s Chief Technology Officer Jake Leach answers your questions about adhesive, direct to watch, accuracy, and even mentions the G8. Here’s more information about the…
Could this finally be a big shake up in the price of insulin? Civica Rx plans to sell the most popular types of fast and long acting insulin for a flat price of 30-dollars a vial. This week you’ll hear from Ned McCoy, Civica’s Chief Operating Officer. He explains why they’re confident this will work,…
There’s been a lot of excitement recently about stem cell transplants and progress toward using this as a functional cure for type 1. There are a few separate groups working on this, this week we’re talking to ViaCyte to get past the hype and look at the real progress here. You’ll hear from ViaCyte’s Head…
In February, the FDA approved the Eversense E3 for 180 day wear. That means you could have a CGM working – with no sensor changes needed – for up to six months. That’s been available in Europe for a while, but in the US it’s been a maximum of three months. As you’ll hear, the…
Last fall, Sigi pump received Breakthrough Device Designation from the US FDA. Although it’s still a long way from being released, Sigi is very intriguing; it uses some of the best parts of existing pump systems. Pim Von Wesel is Co-CEO of AMF Medical, the company that makes the Sigi Pump. We’ll talk about what…
The US FDA has approved Insulet’s Omnipod 5 Automated Insulin Delivery System. This system was submitted more than a year ago but has been delayed due to COVID 19. Stacey talks to Dr. Trang Ly, Senior Vice President & Medical Director at Insulet Corporation who explains what makes this system different from the other AID…
Take a deep dive into the future of Tandem Diabetes. In December, the company laid out an ambitious 5-year plan to update software, move to a smaller pump and ultimately a tubeless version. Company leaders say they want to think even bigger and we’re talking to Chief Strategy Officer Elizabeth Gasser. We’ll go through the…
This week, Dexcom CEO Kevin Sayer spoke to the JP Morgan Healthcare Conference about the G7 and beyond. We talk about information from that presentation and get to as many of your questions as time allows. This interview took place on Tuesday Jan 11 and much of what we discussed isn’t FDA approved. Dexcom presentation…
We’re taking a quick look back at 2021 and a longer look ahead to 2022 and beyond. Stacey is joined by DiabetesMine Managing Editor Mike Hoskins for a fun talk about technology, trends and even few rumors in the diabetes community. As always, please remember this podcast is not intended as medical advice. If you…
When we heard about a new seven day infusion set approved this past summer, we had a lot of questions! We’ve been told since the very first day of pumping to only use the inset for 3 days tops and to always rotate the site. How did they get seven days out of one of…